"The EDSS has a number of limitations and may also measure changes that are not related to MS, such as older age and multiple ...

A multiple sclerosis patient shares essential guidance from her 13-year diagnostic journey, offering hope and practical tips ...

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Multiple Sclerosis.

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...

Most MS treatments don't increase the risk for miscarriage or major birth defects when used during pregnancy, an analysis ...

MP-1032 is under clinical development by MetrioPharm and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase I drugs for Multiple Sclerosis have a 72% phase transition success ...

Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...

Memorial University researcher Michelle Ploughman says artificial intelligence can analyze health data in ways people can't, ...

Significant reductions seen in birth weight with exposure to certain DMTs, and increase seen in rate of small for gestational age ...

Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...